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N. Uldbjerg7, M. Porteus3, N.R. Roan4,5, M. Nyegaard 1, P.W. Denton 8,9 & M.R. Jakobsen 1

Plasmacytoid dendritic cells (pDC) are essential for immune competence. Here we show that
pDC precursor differentiated from human CD34+ hematopoietic stem and progenitor cells
(HSPC) has low surface expression of pDC markers, and has limited induction of type I
interferon (IFN) and IL-6 upon TLR7 and TLR9 agonists treatment; by contrast, cGAS or RIG-I
agonists-mediated activation is not altered. Importantly, after priming with type I and II IFN,
these precursor pDCs attain a phenotype and functional activity similar to that of peripheral
blood-derived pDCs. Data from CRISPR/Cas9-mediated genome editing of HSPCs further
show that HSPC-pDCs with genetic modiﬁcations can be obtained, and that expression of the
IFN-α receptor is essential for the optimal function, but dispensable for the differentiation, of
HSPC-pDC percursor. Our results thus demonstrate the biological effects of IFNs for regulating pDC function, and provide the means of generating of gene-modiﬁed human pDCs.
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lasmacytoid dendritic cells (pDCs) are key effectors in
cellular immunity with the ability to not only initiate
immune responses but also to induce tolerance to exogenous and endogenous antigens1. pDCs are distinct from conventional DCs (cDCs) as they express high levels of interferon
regulatory factor 7 (IRF7) and they primarily sense pathogens
through Toll-like receptor (TLR) 7 and 91,2. Through these
pattern-recognition receptors, pathogen-derived nucleic acids can
activate pDCs to produce high levels of type I interferon (IFN).
Furthermore, activated pDCs link the innate and adaptive
immune system together via cytokine production combined with
antigen-presenting cell (APC) activity. This dual role makes
pDCs essential for attaining an antiviral state during infections,
propagating adjuvant activity in the context of vaccination, and
promoting immunogenic antitumor responses1,3,4. Conversely, a
delicate balance is essential, as hyper-activation of pDCs has been
associated with the pathogenesis of several diseases including viral
infections, systemic lupus erythematosus (SLE), and
tumorigenesis1,2. Collectively, pDCs have a key and multifaceted
role in the immune system, prompting research into their
development and mechanisms of action.
IFNs constitute pleiotropic effectors, which exert a fundamental role during inﬂammation and immune responses, and
recently their activity has been implicated in regulating hematopoietic homeostasis5–7. Mice deﬁcient for the type I IFN receptor
(IFNAR) and STAT2 show decreased numbers of pDCs within
peripheral blood, as well as reduced capacity to mature upon
TLR7 stimulation8,9. Moreover, neonatal mice stimulated with
type I IFN were found to have increased numbers of pDCs in the
periphery8. Accordingly, type I IFNs have been shown to promote
the expression of Flt3, the receptor for Flt3-L, which is known to
be one of the primary physiological factors mediating DC
homeostasis10–12. On the other hand, type I IFNs that were
induced during systemic viral infections were found to negatively
regulate pDC numbers via the intrinsic apoptosis pathway13.
Thus, IFNs appear to regulate key aspects of murine pDC biology,
including development, apoptosis, migration, homeostasis, and
function. However, their role in dictating human pDC development and functions remains incompletely understood. Lack of
biological studies of human pDCs can be ascribed to the very low
frequencies of pDCs within peripheral blood, as pDCs represent
less than 0.1% of peripheral blood mononuclear cells (PBMCs)
and have a short lifespan ex vivo of 1–3 days14. Moreover, genetic
manipulation of immune cells, in particular pDCs, remains a
major challenge as most attempts of introducing genetic material
(e.g., siRNAs) elicit an innate immune response15,16. While studies show that this effect can be reduced with the incorporation of
2′-O-methyl modiﬁcations and using speciﬁc methods of delivery,
precise CRISPR/Cas9 gene editing in pDCs has yet to be reported,
and the poor viability of PBMC-derived pDCs in cell culture
remains a key issue, as the time to induce, observe, and analyze a
corresponding phenotype is highly limited15–19. Thus, technologies that can genetically alter precursor cells prior to the development of pDCs would be a powerful method to circumvent
these limitations.
Previous attempts to investigate pDC biology in vitro have led
to the discovery of numerous culture conditions that support
both expansion and differentiation of CD34+ HSPCs into cells
with pDC-like phenotypic characteristics20–25. However, the total
yield of pDCs has been low, and the similarity to blood-derived
pDCs has thus far not been validated. Importantly, the biological
effects of IFNs on human pDC maturation and function has not
been investigated.
Here we describe a culture protocol focusing on the yield and
biological characteristics of human pDCs. We show that by using
an optimized combination of cytokines and growth factors, an
2

average of 81 (±20) pDCs per single HSPC can be generated,
which outperforms other available protocols. Upon extensive
evaluation of the functional and phenotypic features of the
HSPC-derived pDCs in comparison to canonical peripheral
blood-derived pDCs, we identify a hitherto unknown precursor
pDC phenotype that displays low expression of pDC-speciﬁc
markers and poor functional activation when stimulated with
synthetic TLR7 and TLR9 agonists. Upon priming with type I and
II IFNs, we ﬁnd that this immature phenotype shifts toward a
canonical pDC phenotype with full functional activity, highlighting the requirement of positive stimuli in the form of IFNs
during in vitro human pDC development. Notably, we also
demonstrate that genetically modiﬁed pDCs can be derived from
CRISPR/Cas9 gene-edited CD34+ HSPCs, and that knockout of
the type I IFN receptor abrogates TLR7 and TLR9-mediated
innate sensing.
Results
Expansion and differentiation of HSPCs pDC. Initially, we
investigated various culture conditions reported earlier to support HSPC survival, proliferation, and differentiation toward
cells with pDC lineage characteristics. In validation of our
experimental approach, we ﬁrst reproduced outcomes from past
published protocols and made direct comparisons with our
culture system20–25 (Fig. 1a, b). As baseline condition, we
implemented a previously reported pDC differentiation protocol
entailing culturing cells 21 days in medium containing
the cytokines and growth factors Flt3-L, TPO, and interleukin-3
(IL-3)20. To stimulate expansion of progenitor cells during differentiation we added SCF26 and SR127, and observed far greater
expansion when both factors were included (240 fold ± 42
compared to 35 fold ± 26 in baseline culture; Fig. 1b). Bloodderived pDCs lack the expression of lineage-speciﬁc surface
markers (i.e. CD3, CD14, CD16, CD19, CD20, and CD56) and
the conventional DC marker CD11c1. Therefore, after the 21-day
in vitro differentiation protocol, we enriched for pDCs by
negative selection for linnegCD11cneg cells by immunomagnetic
separation and quantiﬁed the cells obtained. For simplicity these
cells are hereafter referred to as HSPC-pDCs, despite the fact that
no further phenotypic validation had been performed (Fig. 1c, d
and Supplementary Fig. 1a–c). Importantly, SCF and SR1 proved
to be indispensable additives to achieve an abundant and
pure population of HSPC-pDC. We obtained an average yield of
81 (±20) HSPC-pDCs per single HSPC, corresponding to a total
of 16.2 × 106 HSPC-pDCs ± 4.2 × 106 per starting 0.2 × 106
HSPCs. This protocol is a 57-fold improvement in pDC yield
relative to the published protocol of generating HSPC-derived
pDCs20.
HSPC-pDCs display an immature precursor phenotype. Next,
we examined whether the generated HSPC-pDCs were phenotypically and functionally equivalent to blood pDCs. Blood pDCs
are characterized as being linnegCD11cneg, while being positive for
CD123 (IL3Rα), CD303 (BDCA2), CD304 (BDCA4), CD4, and
HLA-DR1,28–30. At culture day 21, we observed that the majority
of HSPC-pDCs were positive for CD123, CD303, CD4, and
HLA-DR, but only about 10% expressed CD304 (Fig. 2a and
Supplementary Fig. 2a, b). Compared to blood-collected pDCs,
HSPC-pDCs had signiﬁcantly lower surface expression levels of
these receptors as determined by mean ﬂuorescence intensity
(MFI) values (Fig. 2b and Supplementary Fig. 2b, c). While the
HSPC culture conditions utilized were initially essential for
expansion and survival, we hypothesized that continued incubation of cells in this cocktail arrested development of HSPC-pDCs.
Such an outcome could result in the observed deﬁciencies relative
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Fig. 1 Generation of pDCs from hematopoietic stem and progenitor cells (HSPC-pDC). a Graphical illustration of the generation of HSPC-pDCs from
HSPCs. CD34+ HSPC were isolated from human umbilical cord blood (CB). Brieﬂy, cord blood mononuclear cells (CBMC) were recovered by FicollHypaque density-gradient centrifugation. CD34+ HSPCs were then isolated using anti-CD34 immunomagnetic beads. Next, 2 × 105 CD34+ HSPC were
cultivated for 21 days with factors promoting the expansion and differentiation of cells. At day 21, the cell suspension was magnetically enriched for
linnegCD11cneg pDCs using negative immunomagnetic selection. b Total numbers of suspension cells measured at the experiment start (day 1) and the
consecutive culture days (4, 8, 12, 16, 18, and 21) with the indicated factors in the medium. c Representative ﬂow cytometry plots showing lineage and
CD11c markers before and after enrichment of pDCs. d Total numbers (upper panel) or percent yield (lower panel) of HSPC-pDCs generated after
magnetic enrichment (negative selection) at day 21 from Flt3-L, TPO, IL-3 culture supplemented with indicated growth factors. Error bars represent ± SEM
of four donors. Statistical analysis was performed using one-way ANOVA (d) followed by Bonferroni post hoc test

to blood pDCs. To test this, HSPC-pDCs were cultured for an
additional 24 h (Day 21 + 1) in medium supplemented with only
IL-3 to support survival (Fig. 2c, d). Removal of growth factors
led to an increase in surface expression of all the pDC-related
markers compared to cells on day 21, but the emerging phenotype
still did not recapitulate the phenotype of blood pDCs (Fig. 2d
and Supplementary Fig. 3a–c). We then examined whether these
HSPC-pDCs at day 21 or day 21 + 1 were able to respond to
classical pDC activators, i.e. synthetic TLR7 and TLR9 agonists.

Both cell populations were found to produce signiﬁcantly less
type I interferon and IL-6 compared to blood pDCs (Fig. 2e, f).
Nevertheless, upon stimulation with lipofectamin-formulated
agonists directed at cytosolic DNA and RNA sensors, HSPCpDCs produced high levels of type I IFN, indicating that HSPCpDCs do not lack the capacity to induce innate immune
responses (Fig. 2g). However, as was the case for TLR stimulation,
the type I IFN responses was found to be lower compared to
blood pDCs. Taken together, we hypothesize that day 21 HSPC-
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Fig. 2 HSPC-pDCs elicit a precursor-pDCs phenotype. a Phenotypic analysis of pDC-associated markers on HSPC-pDCs at day 21 using Flow Cytometry.
For gating strategy, see Supplementary Fig. 2a, b. b Surface expression levels of pDC-related markers on enriched HSPC-pDCs at day 21 in comparison to
blood pDCs. c Graphical illustration of the experimental setup of removal of growth factors for 24 h after the 21-day differentiation. After enrichment of
HSPC-pDCs at day 21, cells were depleted of growth factors (except IL-3). After 24 h (day 21 + 1) HSPC-pDCs were harvested for phenotypic or functional
analyses. d Phenotypic comparison of HSPC-pDCs at day 21 or day 21 + 1. e, f Levels of type I IFN (e) or IL-6 (f) after stimulation with TLR7 or TLR9
agonists of enriched HSPC-pDCs cells at day 21, HSPC-pDCs Day 21 + 1IL-3, or blood pDCs. g Levels of type I IFN after stimulation with agonists directed at
cytosolic DNA and RNA sensors of enriched HSPC-pDCs cells at day 21, HSPC-pDCs Day 21 + 1IL-3, or blood pDCs. Data shown are ± SEM of three donors.
Statistical analysis was performed using regular two-way ANOVA (b, d–g) followed by Bonferroni post hoc test

pDCs represent a phenotypic and functional precursor to canonical pDCs, deﬁning them as immature HSPC-pDCs.
Interferon priming leads to a canonical pDC phenotype. Recent
studies have emphasized the role of IFNs in murine pDC
4

development, homeostasis, and function8–10,13. Thus, we hypothesized that exogenous IFN may be required to drive HSPCpDCs into a phenotype that more closely resembles blood pDCs
and that these cells would then be able to respond efﬁciently to
TLR agonists. To test this, we evaluated the effects of a 24 and
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Fig. 3 Upon IFN priming, HSPC-pDCs can be modulated to become classical pDCs. a Graphical illustration of the experiment setup of HSPC-pDC priming.
After enrichment, HSPC-pDCs were primed in medium supplemented with IFN-β + γ or IL-3 alone. After 72 h (day 21 + 3) primed cells were harvested for
phenotypic or functional analyses. b Surface expression levels of pDC-related markers on HSPC-pDC cells after priming for 72 h with IFN-β + γ (Day 21 +
3IFN β+γ) and blood pDCs. c, d Type I IFN (c) or IL-6 (d) response of blood pDCs, unprimed or IFN-primed HSPC-pDCs cells to TLR7 and TLR9 agonists.
e Type I IFN response of HSPC-pDCs primed with titrated concentrations of IFN-β + γ before being stimulated with the TLR7 agonist R837. Data shown
are ± SEM of three donors. Statistical analysis was performed using regular two-way ANOVA (b–d) followed by Bonferroni post hoc test

72 h β- and/or γ-interferon exposure on HSPC-pDCs initiated at
Day 21 (Day 21 + 1IFN-β+γ and Day 21 + 3IFN-β+γ). Consistent
with our hypothesis, we found that IFN-primed HSPC-pDCs
acquired a surface phenotype proﬁle that strongly resembles
blood pDCs with no signiﬁcant differences in the expression of
CD303, CD304, CD4, or HLA-DR (Fig. 3a, b and Supplementary
Fig. 4a–d). However, CD123 (IL-3 receptor) expression was still
signiﬁcantly lower, which has been reported to be caused by the
supplementation of IL-3 during culture of pDCs31. Next, we
challenged IFN-primed HSPC-pDCs with synthetic TLR7 and
TLR9 agonists and evaluated the type I IFN and IL-6 responses.
Intriguingly, we now observed that type I IFN and IL-6 reached
levels comparable to that produced by stimulated blood pDCs
(Fig. 3c, d and Supplementary Fig 5a–d). While the TLR7- and
TLR9-mediated type I IFN responses were potent in IFN-primed
HSPC-pDCs, the type I IFN response upon stimulation with
synthetic agonists directed at cytosolic RNA and DNA sensors
was less affected by IFN priming, indicating that IFNs mainly
play a role in TLR7- and TLR9-dependent innate immune
responses (Supplementary Fig. 6a, b). Notably, IFN-γ priming

predominantly promoted the secretion of IL-6, but was less
effective at promoting a type I IFN response in comparison to
IFN-β priming after synthetic TLR7 and TLR9 agonist stimulation (Supplementary Fig. 5a–d). Expression levels of CD303,
CD304, and HLA-DR were increased by IFN-γ priming. Together, these data indicate that the signaling pathways of type I and
II IFNs do not merely overlap, but rather lead to synergistic
interferon-dependent signaling pathways (Supplementary
Fig. 4a–d). By titrating in different amounts of exogenous IFN-β
and IFN-γ, we found that HSPC-pDCs were able to acquire the
phenotypic and functional traits of blood pDCs, using as little as
30 U/mL each of recombinant cytokine for priming (Fig. 3e and
Supplementary Fig. 7a–e). To reduce potential negative effects of
lot-to-lot variations in fetal calf serum, we also evaluated the
phenotypic and functional appearance of HSPC-pDCs using
commercially available serum-free media (SFEM II), which
showed similar yield, pDC surface expression, and responses
following TLR stimulation (Supplementary Fig. 8a–c).
Previous studies have identiﬁed rare pre-DC subsets, which,
due to functional and phenotypic similarities to pDCs, may have
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inadvertently been considered as mature pDCs in prior
studies32,33. We therefore next evaluated if pre-DCs were present
within the HSPC-pDC population. Pre-DCs are characterized as
LinnegCD123+CD303+CD304+, but in addition express markers
unrelated to pDCs, including CD2, CD5, and CD33. Furthermore, they secrete cytokines produced by cDCs such as IL-12
(refs.32,33). After immunomagnetic pDC enrichment on culture
day 21, we observed that HSPC-pDCs were negative for the preDC marker CD33. Importantly, IFN priming of HSPC-pDCs did
not lead to increased CD33 expression, indicating that IFN
priming did not lead to generation of pre-DCs (Supplementary
Fig. 9a, b). Notably, while it was possible to detect pre-DCs in a
PBMC population, the subset was not detectable in the enriched
blood pDC population, indicating that the enrichment procedure
removes the blood pre-DC subset (Supplementary Fig. 9c, d). We
further evaluated cell-surface expression of CD2, CD5, and
CX3CR1, which have also been reported to deﬁne the pre-DC
population. CD2 and CD5 were not expressed by HSPC-pDCs,
neither at day 21 nor after IFN priming (Supplementary Fig. 9e,
f). An increase in CX3CR1 expression was observed upon IFN
priming, which reached an expression level similar to that of
blood pDCs (Supplementary Fig. 9e, f). Finally, HSPC-pDCs at
day 21 or IFN-primed HSPC-pDCs did not produce IL-12 upon
stimulation with cDC-activating stimuli (R848, poly I:C or LPS),
further supporting our conclusion that the previously described
pre-DCs are not present within the HSPC-pDC population
(Supplementary Fig. 10a–c).
Based on our observations that HSPC-pDCs from day 21 of
culture displayed a previously undescribed precursor phenotype,
we next searched for this population in vivo. We puriﬁed
LinnegCD11cneg cells from CB and analyzed the cells by ﬂow
cytometry for the expression of CD123 and CD303. Interestingly,
we observed that fresh CB-pDCs contained two distinct
populations, one with a mature phenotype (CD123high
CD303high) and one with a precursor phenotype
(CD123dimCD303dim) (Supplementary Fig. 11). Importantly, as
observed for HSPC-pDCs, IFN priming increased the population
of CD123highCD303high cells, indicating the presence of a pDC
precursor phenotype in CB. However, a maturation was also
evident during culture with IL-3 alone, albeit not to the same
extent. A recent study argues that human pDCs are capable of
self-priming by continuously secreting small amounts of type I
IFN, enabling pDCs to retain a response through TLR7 and
TLR9. This may partly explain the minor phenotypic shift we
observed for unprimed cells34. Finally, we tested whether priming
of HSPC-pDCs led to an altered response to TLR7 and TLR9
agonists via increased mRNA expression of genes involved in the
TLR signaling pathway. The expression levels of IRF7 and TLR7
were signiﬁcantly increased after IFN priming, whereas the
expression of TLR9 remained unchanged (Supplementary Fig. 12).
To test if exogenous priming of HSPC-pDCs initiated selfpriming, we removed IFN-β and IFN-γ from HSPC-pDCs after
one day in culture, and let the cells rest for an additional day in
medium with IL-3 alone (Supplementary Fig. 13a). Priming of
HSPC-pDCs led to increased expression of the IFN-α mRNA
isotypes tested (α4, α16), and this expression was maintained after
the resting phase, suggesting that self-priming occurs in this
culture system (Supplementary Fig. 13b).
HSPC-pDCs transcriptional responses. To more comprehensively assess the transcriptional response of HSPC-pDCs to
priming and TLR7 activation, we next performed whole transcriptome analysis. Cells from blood pDCs (n = 4) and primed
HSPC-pDCs (n = 4) were mock-treated or subjected to 24 h of
activation through TLR7. RNA was then immediately processed
6

and analyzed by RNA-seq. Pathway analysis on genes differentially expressed between stimulated and non-stimulated cells
was used to determine which biological processes were enriched during stimulation of blood pDCs and primed HSPCpDCs (Fig. 4a). The most highly activated biological processes
were shared between the two cell types, although the HSPCpDCs tended to be more enriched for the shared pathways.
When we examined the upstream regulators predicted to be
responsible for inducing the transcriptional changes, we found
a striking concordance between HSPC-pDCs and blood pDCs
(Fig. 4b). Gene expression changes related to TLR7 signaling
interactome (visualized in the outer circle) were strongly
activated in both blood pDCs and HSPC-pDCs, supporting the
fact that both cell types are fully capable of responding to the
TLR7 agonist (Fig. 4c). The increased numbers of genes in
the interactome of the HSPC-pDCs versus blood pDCs do
indicate that a larger genetic shift from precursor HSCP-pDCs
to fully TLR7-responsive pDCs is needed, supporting the fact
that our day 21 HSCP-pDCs are less activated than unstimulated blood pDCs.
HSPC-pDCs capacity to adopt an antigen-presenting phenotype. An important but often neglected function of pDCs is their
capacity to function as APCs. To test whether IFN priming affects
the capacity of HSPC-pDCs to adopt a phenotype reminiscent of
APCs, we next evaluated the expression of classical APC activation markers (CD40, CD80, CD83, and CD86)1. Unprimed as
well as IFN-primed HSPC-pDCs treated with TLR7 agonist displayed comparable elevated expression of CD80 and CD83
(Fig. 5a and Supplementary Fig. 14). In contrast, expression of
CD40 and CD86 was signiﬁcantly higher in IFN-primed cells as
compared to their unprimed counterparts.
To extend these observations, we next investigated if HSPCpDCs were capable of activating T cells after pulsing them with
CMV antigens. For this, we pulsed IFN-primed and TLR7
activated HSPC-pDCs with a cocktail of CMV-derived peptides
(consisting of 14 peptides, each corresponding to a deﬁned HLA
class I-restricted T cell epitopes) and then co-cultured the cells
with PBMCs derived from CMV-seropositive donors (Fig. 5b).
First, to conﬁrm that all three seroconverted donors responded to
the CMV peptides, we merely used the APCs within the PBMC
cultures to take up and present the CMV peptides to CD8+
T cells (Fig. 5c). Next, we pulsed HSPC-pDCs with the CMV
peptide cocktail and after extensive washing added them to the
same three PBMC donors. Activation of CD8+ T cells as
measured by IFN-γ production was only evident when the cocultured HSPC-pDCs had been pre-loaded with CMV (Fig. 5d).
Together, these data indicate that activated HSPC-pDCs can
present peptides and activate antigen-speciﬁc T cells.
A major drawback when using blood-derived pDCs is their
short lifespan in culture, limiting the window of opportunity for
in vitro evaluations. To estimate the lifespan of HSPC-pDCs in
prolonged culture studies, we next compared viability of HSPCpDC to blood pDCs over a prolonged culture of 12 days post
differentiation, in medium with IL-3+/− IFN-β+γ. Within one
day of isolation, only 50% of blood pDCs were viable. In contrast,
HSPC-pDCs demonstrated superior survival during this period
(Fig. 5e and Supplementary Fig. 15a–f). After 5 days of culture,
the viability of HSPC-pDCs decreased to 60%. Notably, after
8 days of culture, only 10% of blood pDCs were viable, whereas
unprimed HSPC-pDCs remained at 60% viability (Fig. 5e, f and
Supplementary Fig. 15a–f). While viabilities were similar during
the ﬁrst 5 days between IFN-primed and unprimed HSPC-pDCs,
a signiﬁcant drop in viability was evident for IFN-primed cells
from day 5 to 12 (Supplementary Fig. 15c).

NATURE COMMUNICATIONS | (2018)9:3525 | DOI: 10.1038/s41467-018-05816-y | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05816-y

b

Biological-process enrichment
among DE genes

IFNG
IFNA2
TGM2
STAT1
IRF7
PRL
TLR9
TNF
TLR7
IRF1
IL1B
IRF3
TRIM24
NKX2-3
IFN beta
IFNL1
IL1RN
NFkB (complex)
TLR4
TNFSF10
MAPK1
IFNB1
Ifnar
IL27
TLR3
SIRT1
P38 MAPK
IRF5
IL21
CSF2
SOCS1
IFNA1/IFNA13
EIF2AK2
OSM
SMARCA4
IFN alpha/beta
Ifn
MAVS
NOS2
IL5
PRKCD
BRCA1
CHUK
IL10RA
INSIG1

Immunological disease
Infectious diseases
Antimicrobial response
Inflammatory response
Cellular function and maintenance
Cell death and survival
Dermatological diseases and conditions
Organismal injury and abnormalities
Cellular development
Blood pDC

Cellular growth and proliferation
5

10

15

20

25

30

35

40

45

50

TICAM1
PRDM1
AGT
FOS
IFI16
IL2
APP
SAMSN1
SNCA
DDX58
PTGER4
ACKR2
KITLG
MAPK14
STAT4
DOCK8
IL17A
JAK1/2
RELA
SP1
FN1
SASH1
TNFSF11
SPI1
IL6
SREBF1
SELPLG
CD38
LDL
CD40LG
BTK
JAK2
PAF1
STAT2
FOXO1
POR
EGR1
PTGS2
RAF1
IFNAR1
MIF
mir-223
JAK1
TLR2

Blood pDC
HSPC-pDC

HSPC-pDC

0

Upstream
regulators

55

–Log (p - value)

5
0
–5

Blood pDC
HSPC-pDC

a

c
FCER1G ICAM1
CXCL8

IER3
FCER1G

IFI35

CEBPB

IER3
IFI35

CD69

IFI44L
CDKN1A

IFI44L
IFIT1
CCR7

CD83
IFIT3

IFIT1

CCR7

CCNB1

Prediction legend
More extreme in dataset
Increased measurement

Less

IFITM1

Decreased measurement

CCL2

IFIT3
IL10RA

BCL2A1

BCL2A1

TLR7

Predicted relationships

TLR7

IL1B

IFITM1

ZC3H12A
IRF7

Leads to activation
Leads to inhibition
Finding inconsistent
with state of downstream
molecule

STAT2

TNF

ISG15

IRF9
STAT1

STAT2

MX1

ISG15
STAT1
MX1
SOD2

MX2
SOCS1
RSAD2 OAS3

RSAD2
MX2
OAS3

OAS2

OAS2

HSPC-pDCs

Blood pDCs

Fig. 4 HSPC-pDCs and blood pDCs exhibit shared transcriptomic pathways. a Top 10 biological processes enriched in the set of differentially expressed
genes and their associated P values for blood pDCs (black) and IFN-primed HSPC-pDC (gray) after 24 h stimulation with a TLR7 agonist. b Heat map
(z-score) of both activated and inhibited upstream regulator genes within the top biological process corresponding to panel (a). c Illustration of regulated
genes within the TLR7 pathway of after stimulation of blood pDCs and HSCP-pDC, respectively

Production of genetically modiﬁed HSPC-pDCs. To provide
evidence that IFN signaling is essential for differentiation and/or
maturation of HSPC-pDCs, we set out to genetically remove the
IFN receptor. Whereas genetic manipulation of pDCs is currently
not possible (discussed in the Introduction), recent advances in
the CRISPR/Cas9 technology have resulted in successful and
efﬁcient gene editing of CD34+ HSPCs35–39. Thus, we hypothesized that gene-edited pDCs could be generated successfully by
initial modiﬁcation of CD34+ HSPCs and subsequent differentiation into pDCs. We employed a gene editing strategy where
synthetic chemically modiﬁed sgRNAs and recombinant Cas9
protein, which forms a ribonucleoprotein (RNP) complex, were
delivered to CD34+ HSPCs by electroporation35,36 (Fig. 6a). The
sgRNAs were designed to target the open reading frame within

the ﬁrst exon of IFNAR1 (subunit of the type I IFN receptor) and
MyD88. The latter target was included for its established role in
TLR-mediated responses1,10,34. A previously published sgRNA
targeting the safe harbor gene CCR5 was used as a negative
control38. A range of sgRNAs for MyD88 and IFNAR1 were
initially screened for their potency to induce targeted gene disruption by insertions and deletions (Indels) by plasmid electroporation in K562 cells (Supplementary Fig. 16a). The three
sgRNAs with the highest efﬁcacy for each target were then tested
as synthetic sgRNAs with chemically modiﬁed nucleotides at both
termini by Cas9 RNP delivery by electroporation of CD34+
HSPCs, leading to the selection of a single potent sgRNA for each
target gene yielding 73.4 ± 4.5% and 86.7 ± 2.7% Indel frequencies
for MyD88 and IFNAR1, respectively (Supplementary Fig. 16b).
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The two selected sgRNAs and the CCR5 control sgRNA were then
used in CD34+ HSPCs that following a 3-day recovery phase after
electroporation were differentiated into pDCs (Fig. 6a, b).
Importantly, no change in the proliferation rate and total cell yield
was observed during differentiation (comparing Figs. 1b and 6b)
and high Indel rates were observed pre- and post differentiation
(Fig. 6c and Supplementary Fig. 16c, d). When we evaluated the
overall yield of HSPC-pDCs on day 21 we observed a ~4-fold
decrease in yield compared to previous experiments. We ascribed
this to either the nucleoporation procedure itself, as mock8

electroporated cells were equally affected, or to the increased
period of cultivation (Fig. 6d). Analysis of Indel frequencies after
immunomagnetic pDC enrichment conﬁrmed that HSPC-pDCs
had similar levels of Indels as the total non-enriched cell population (Supplementary Fig 16d), and MyD88 protein levels
determined by western blotting conﬁrmed potent knock-down
(Fig. 6e). IFNAR1-targeted HSPC-pDCs showed reduced capacity
to induce downstream signaling through IFNAR, as stimulation
with IFN-β failed to induce STAT1 phosphorylation, whereas
signaling through the IFN-γ receptor was unaffected (Fig. 6e and
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Supplementary Fig. 16e, f). Next, the HSPC-pDCs were analyzed
for two pDC phenotypic markers (CD123 and CD304) and for
functionality after IFN priming. CRISPR/Cas9-treated cells
showed expression of both surface markers and expression of
both markers increased markedly following IFN priming, which
recapitulates earlier observations (Fig. 6f, g and Supplementary
Fig. 17a, b).
MyD88-targeted HSPC-pDCs were then IFN-primed and
stimulated with TLR7/9 agonists. In both cases of TLR
stimulation, type I IFN and IL-6 induction were signiﬁcantly
decreased in the KO cells (Fig. 6h, i and Supplementary Fig.17c).
Interestingly, when we evaluated the response to TLR agonists in
HSPC-pDCs targeted at the IFNAR1 gene, we found that the cells
displayed a decreased capacity to induce type I IFN, supporting
our previous ﬁndings that type I IFN feedback is a prerequisite for
TLR7- and TLR9-dependent type I IFN induction (Fig. 6h).
Moreover, IL-6 production after stimulation was also diminished
in IFNAR1 sgRNA-targeted HSPC-pDCs, indicating type I IFN
signaling is important for TLR7 and TLR9 activity in pDCs
(Fig. 6i). Of note, in some donors we observed a full abrogation of
the type I IFN response, despite ~20% of the cells still possessing
the WT allele of IFNAR1 (as estimated from the TIDE analysis),
indicating an ampliﬁcation loop may be required for the TLR7/9mediated type I IFN response to occur in the remaining cells
(Fig. 6h, i and Supplementary Fig. 17d). In summary, our results
identify a hitherto unknown role of interferons in promoting the
activation of human precursor pDCs into a phenotype that
strongly resembles that of pDCs derived from peripheral blood.
We also demonstrate that gene-edited HSPC-pDCs can be
produced by initially modifying CD34+ HSPC before differentiation to HSPC-pDCs. Using this system, we conﬁrm that while
MyD88 and IFNAR1 do not appear to be important in human
pre-pDC development, they are essential for functional pDC
immune responses upon stimulation through the TLR pathway.
Discussion
Here we present the ﬁrst evidence that IFN priming is essential
for the ability of pDCs to mount a robust and efﬁcient innate
immune response. We show this using a novel in vitro approach
to expand and differentiate human CD34+ HSPCs, ﬁrst into
precursor pDCs, and then into fully mature and functional pDCs.
The power of the system is found within its simplicity, the
increased survival of the pDC, high cell yields, and phenotypic
and functional resemblance of these HSPC-derived cells to bloodcollected pDCs. In addition, the approach is readily amenable for
genetic manipulation by CRISPR/Cas9 approaches. This is an
important beneﬁt of this culture system, since inhibition of gene
expression in by RNAi-based methods in pDCs can be problematic due to non-speciﬁc immune activation through, e.g. RIG-I
or TLR3/7/815,40–42. Furthermore, pDCs in general have been
difﬁcult to genetically modify, and even siRNAs engineered to be
less immuno-stimulatory, such as 2′O-methyl modiﬁcations,
inadvertently antagonizes TLR7, which affects downstream
assays43–45. Moreover, designing a non-immuno-stimulatory
siRNA that retains RNAi potency is often difﬁcult and requires
trial and error46. Our demonstration that CRISPR/Cas9-based
gene editing can be accomplished in human pDCs will lay the
groundwork for future elucidation of speciﬁc molecular pathways
involved in pDC development and function. We also note that
our use of a transient RNP-based delivery system in early
developing HSPCs will reduce the risk of potential off-target
effects that are more prominent during continuous expression of
a gene cassette (e.g. lentiviral transduction) also used in CRISPR/
Cas9-based approaches.
10

While previous culture systems have allowed for the generation
of pDCs, our work identiﬁed a limitation of those studies, namely
that such previously generated HSPC-pDCs display a precursor
phenotype, that must be overcome in order to generate pDCs that
resemble the majority of pDCs found in the bloodstream. Type I
IFN responses in in vitro-generated pDC after stimulation with
the synthetic TLR9 agonist CpG-A have previously been reported,
while synthetic TLR7 agonists, to our knowledge, have never been
tested20,21,23–25. Moreover, limited comparisons to blood pDCs
have been conducted20,21,23–25. We found that unprimed HSPCpDCs produced type I IFN in response to CpG-A, although at
signiﬁcantly reduced levels compared to blood pDCs. In addition,
no type I IFN responses were observed upon stimulation of
HSPC-pDCs with synthetic TLR7 agonists. Notably, the observed
precursor state of unprimed HSPC-pDCs shares many of the
intrinsic features of neonatal pDCs, including a lack of a TLR7mediated response and decreased surface expression of pDC
markers47–50.
Of note, three distinct maturation stages of pDCs have recently
been identiﬁed by Martín-Martin et al.51 within adult bone
marrow. These stages were separated by their expression levels of
pDC phenotypic markers (CD123, CD303, and CD304), and the
capacity to produce type I IFN upon synthetic TLR9 agonist
stimulation51. Martín et al. found that pDCs from peripheral
blood produced markedly higher levels of type I IFN in comparison to bone marrow-derived pDCs. We identiﬁed two
populations of linnegCD11cneg cells within CB separated by their
expression levels of the pDC markers CD123 and CD303.
Importantly, IFN priming increased the fraction of cells with high
expression levels of these pDC markers, whereas the population
with intermediate expression decreased. Of note, an increase in
the CD123highCD303high population was observed upon IL-3
conditioning alone, suggesting that self-priming capabilities exist
which can potentially overcome the need of exogenous priming
with IFN34. Overall, this indicates that pDCs undergo different
stages of development before reaching phenotypic and functional
maturity.
Our ﬁndings indicate that immature pDCs require the withdrawal of precursor-supporting growth factors and the addition
of a positive factor in order to attain activity and respond to
pathogens. Infection and other physiologic stresses are known to
stimulate cytokine output, in particular type I and II IFNs, both
regionally and systemically, which would support local priming of
pDCs and their trafﬁcking to the site of infection5–7. While IFNs
have traditionally been considered to be antiviral, pro-inﬂammatory, and pro-apoptotic, they have recently also been shown to
regulate survival of activated T cells and promote proliferation of
dormant HSPCs via a STAT1-dependent pathway7,52. Similarly,
Chen et al. reported that IFNAR1−/− and STAT2−/− mice display signiﬁcantly decreased numbers of pDCs within the blood,
supporting our hypothesis that IFN priming is involved in pDC
homeostasis8–10. Moreover, as demonstrated by Vollstedt et al.8
murine pDCs are mobilized in neonatal mice upon IFN-α treatment. Although a direct role of type II IFNs in pDC development
and activation remains to be elucidated, both type I and II IFNs
are known to signal through a JAK–STAT signaling pathway.
Accordingly, it is well-established that many ISGs are regulated
by both factors53. However, other genes are known to be selectively regulated by the two types of IFN, which is likely regulated
by differential activation of different STAT proteins53. Notably,
both type I and II IFNs induce STAT3 phosphorylation, which is
known to induce the transcription factor E2-2, which is directly
involved in pDC development by inducing a number of pDCspeciﬁc genes, including Spi-B, IRF7, TLR7, TLR9, ILT7 (CD85g),
and CD303 (refs.53–56). Accordingly, we observed up-regulation
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of pDC-related markers, including CD123, CD303, and CD304,
upon priming with IFN-β and/or IFN-γ. Furthermore, from the
transcriptomic analysis we saw that priming of HSPC-pDCs with
IFNs resulted in a shared pattern of differentially expressed genes
activating biological pathways as that observed upon stimulation
of blood pDC, suggesting the existence of shared functional
responses in the blood- vs. HSPC-derived pDCs.
Interestingly, we found IFN-γ to be most potent in upregulating pDC-associated surface markers, which may suggest this
cytokine has a higher preference for STAT3-mediated signaling.
However, we found that IFNAR knockdown in HSPC-pDCs
abrogated type I IFN responses to TLR7 and 9 agonists, suggesting that type I IFN feedback is crucial for the TLR function of
pDCs. As type I IFN indirectly signals the presence of a pathogen,
this may in turn serve to regulate the function of the receptors, so
aberrant immune activity is avoided. This is analogously supported by the concept that many proteins implicated in TLR7 and
TLR9 processing or signaling pathways are IFN-regulated,
including IRF7, PLSCR1, and viperin57–60.
While the role of IFNs in human pDC homeostasis remains to
be fully elucidated, it is known that pDCs are involved in the
immunopathogenesis of several autoimmune diseases, including
psoriasis, type I diabetes (T1D), and SLE. These diseases are all
characterized by a distinct “type I IFN signature”, and increased
Th1-mediated type II IFN responses, which is believed to have a
major role in the instigation and severity of disease61–67.
Importantly, pDCs are signiﬁcantly increased within peripheral
blood of patients with SLE and T1D, and in psoriasis patients,
pDCs are recruited to psoriatic plaques64–66,68. Moreover, previous viral infections or IFN-α therapy during hepatitis C infection are known to promote the development of T1D61–65. Taken
together, these studies indicate that a type I and II IFN environment observed during autoimmune diseases or viral infections
serve to mobilize pDCs from the bone marrow. With our ﬁndings
that both type I and II IFNs are critical for HSPC-pDCs to
achieve a functional and phenotypic resemblance to blood pDCs,
our study adds further information on how such factors affect the
functionality of pDCs.
In conclusion, our study demonstrates a previously undescribed crucial role of IFNs in the maturation of human pDCs.
These studies apply a novel in vitro differentiation protocol, and
resulted in the identiﬁcation of a two-step developmental process
of pDCs that entails the initial generation of immature pre-pDCs
that display a poor innate immune response through the classical
endosomal TLR7/9 receptors, followed by subsequent priming by
type I and II IFNs that rapidly matures the cells into a fully
functional phenotype. We believe that this ﬁnding will have
important implications for the understanding of a range of
immune-related disorders.
Methods

Ex vivo generation of pDCs from CD34+ HSPC. CD34+ HSPCs were puriﬁed
from human umbilical cord blood (CB) acquired from donors under informed
consent via either the Binns Program for Cord Blood Research at Stanford University or from Department of Gynecology and Obstetrics, Aarhus University
Hospital, Aarhus. Brieﬂy, mononucleated cells were recovered by standard FicollHypaque (GE Healthcare) density-gradient centrifugation. CD34+ cells were
subsequently isolated using anti-CD34 immunomagnetic beads (positive selection)
following the manufacturer’s instructions (EasySepTM Human cord blood CD34+
positive selection kit, STEMCELL Technologies or CD34 MicroBead Kit UltraPure,
human, Miltenyi Biotec). CD34+ HSPC were either freshly used or cryo-preserved
until future use. For HSPC to pDC differentiation, CD34+ HSPC were plated in 48well plates in RPMI-1640 medium (Lonza), supplemented with 10% heatinactivated fetal calf serum (FCS) (HyClone®), 600 µg/mL L-glutamine (Sigma),
200 U/mL penicillin, and 100 µg/mL streptomycin (Gibco®, Life Technologies).
Notably, we also found it is possible to substitute the culturing protocol with
serum-free conditions, using SFEM II (STEMCELL Technologies) supplemented
with 20 µg/mL streptomycin and cytokines/growth factors. Furthermore, the
cytokines Flt3-L, TPO, and IL-3 (Peprotech) were added as a baseline. In addition

to the baseline, the cytokines SCF, IL-7 (Peprotech), and the chemical StemRegenin
1 (STEMCELL Technologies) were tested individually or in combination at various
concentrations. Cells were cultured at 37 °C, 95% humidity, and 5% CO2 for
21 days. Medium was refreshed every 4 days with medium containing the designated cytokines. Total cell numbers during the cultivation period were determined
using the cell counter Moxi ZTM (ORFLO Technologies) or TC20 (Bio-Rad). At
day 21 HSPC-pDCs were enriched using a negative selection kit that depletes nonpDCs, according to the manufacturer’s protocol (EasySepTM Human Plasmacytoid
DC Enrichment kit, STEMCELL Technologies).
pDC enrichment from peripheral blood. PBMCs were isolated by Ficoll-Hypaque
density centrifugation of normal healthy blood donor buffy coats obtained from
Aarhus University Hospital Blood Bank. Blood pDCs were enriched by negative
selection following the instructions by manufacturer (EasySepTM Human Plasmacytoid DC Enrichment kit; STEMCELL Technologies).
Generation of monocyte-derived dendritic cells (mo-DCs). CD14+ monocytes
were initially puriﬁed from PBMCs by negative immunomagnetic selection
according to the manufacturer's instructions (EasySepTM Human Monocyte
Enrichment kit, STEMCELL Technologies). Puriﬁed monocytes were washed twice
and cultured in six-well plates at a density of 0.5 × 106 cells/mL in 1.2 mL of RPMI1640 medium (Lonza), supplemented with 2% normal human serum type AB
(NHS AB), 600 µg/mL L-glutamine (Sigma), and 20 µg/mL gentamicin (Gibco).
Cultures were established in the presence of 100 ng/mL human GM-CSF (Peprotech) and 20 ng/mL IL-4 (Peprotech). Cells were cultured at 37 °C, 95% humidity,
and 5% CO2 for 6 days. During the cultivation, cultures were supplemented with
fresh medium supplemented with GM-CSF and IL-4. At day 6, cells were functionally evaluated.
Priming of HSPC-pDCs. HSPC-pDCs were cultured in RPMI-1640 medium with
10% heat-inactivated FCS, 600 µg/mL L-glutamine, 200 U/mL penicillin, and
100 µg/mL streptomycin, but depleted for growth factors used for the differentiation process described above. As described in individual ﬁgure legends, medium
was supplemented with 250 U/mL IFN-β (PBL Assay Science), 250 U/mL IFN-γ
(PeproTech), or both cytokines simultaneously (IFN-β + γ). After 24 (day 21 + 1)
or 72 (day 21 + 3) hours, cells were washed in warm medium, and phenotypically
or functionally characterized.
Cell stimulation. For functional characterization, cells were seeded in 96-well
plates. Cells were left untreated or stimulated with stimuli as shown in Supplementary Table 1. During stimulation cells were kept in medium with 20 ng/mL
IL-3. Twenty hours post stimulation supernatants were harvested and kept at −20 °
C until cytokine quantiﬁcations. For phenotypic characterization, IFN-primed or
unprimed cells were seeded in 48-well plates and stimulated for 24 h before phenotypic analysis by ﬂow cytometry.
Measurement of functional type I IFN. Bioactive functional type I IFN was
quantiﬁed in supernatants using the reporter cell line HEK-BlueTM IFN-α/β
(Invivogen). The cell line was maintained in DMEM + GlutaMaxTM-I (Gibco®,
Life Technologies), supplemented with 10% heat-inactivated FCS, 100 µg/mL
streptomycin and 200 U/mL penicillin, 100 µg/mL normocin (InvivoGen),
30 µg/mL blasticidin (InvivoGen), and 100 µg/mL zeocin (InvivoGen). Cells were
passaged using 1× trypsin (Gibco®, Life Technologies). To ensure optimal type I
IFN response and stable expression of the plasmids encoding hIRF9, hSTAT2, and
SEAP, cells were not passaged more than 20 times. For measurement of functional
type IFN, cells were seeded at 3 × 104 cells/well in 96-well plates in 150 µL medium.
Cells were grown as previously described, but without blasticidin and zeocin. The
following day, 50 µL of supernatant from stimulated cells or a type I IFN standard
range was added to the cells. After 24 h of incubation, 20 µL of supernatant from
the HEK-Blue cells was subsequently added to 180 µL QUANTI-BlueTM. SEAP
activity was assessed by measuring optical density (OD) at 620 nm on a microplate
reader (ELx808, BioTEK). The standard range was made with IFN-α (IFNa2 PBL
Assay Science) and ranged from 2 to 500 U/mL.
Enzyme-linked immunosorbent assay. Protein levels of IL-6, IL-12 p70, or IFN-γ
in supernatants were evaluated using ELISA kits for IL-6 (Biolegend), IL-12
(Human IL-12 p70 DuoSet ELISA kit, R&D Systems), and IFN-γ (Human IFN-γ
DuoSet ELISA kit, R&D Systems), following the manufacturer's instructions.
Western blot. To evaluate protein levels, cells were lysed in Pierce RIPA buffer
(Thermo Scientiﬁc) supplemented with 10 mM NaF, 0.2% SDS, 1× protease inhibitor (Roche), and 1× XT sample buffer (Bio-Rad). Whole-cell lysates were heated
at 95 °C for 5 min before being separated on a 10% SDS Bis-Tris Gel (Criterion
TGX gels, Bio-Rad) and blotted onto PVDF membrane (Bio-Rad). Proteins were
stained using primary antibodies (1:1000) directed against MyD88 (D80F5; Cell
Signaling Technology), STAT1 (Cell Signaling Technology 9172), pSTAT1
(Tyr701, D4A7; Cell Signaling Technology, 7649), and vinculin (hVIN-1; SigmaAldrich) and secondary peroxidase-conjugated Afﬁnipure F(abr)2 donkey
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anti-rabbit (IgG) (1:15000) (Jackson Immuno Research). Proteins were detected
using Clarity Western ECL Blotting Substrate (Bio-Rad) followed by visualization
with an ImageQuant LAS4000 mini biomolecular imager (GE Healthcare).
Uncropped scans of important blots are included in the Supplementary Figure 18.
Morphology of cells. To examine the morphology of cells at day 21, cells were
smeared out on glass slides and ﬁxed with methanol. May–Grünwald Giemsa
Staining (Merck) was performed according to the manufacturer’s protocol. Slides
were examined using a Leica DM IL LED microscope.
Phenotypic analysis with ﬂow cytometry. Immunophenotypical analysis was
performed using ﬂow cytometry. Brieﬂy, 2 × 105 cells were spun down and
resuspended in staining buffer (PBS with 0.5% BSA and 0.09% NaN3). Cells were
blocked on ice for 30 min before being stained with ﬂuorochrome-conjugated
antibodies for 30 min. After three washing steps in staining buffer, cells were ﬁxed
in 0.9% formaldehyde. Fluorescence intensities were measured by ﬂow cytometry
either on an LSR Fortessa ﬂow cytometer with four lasers (405, 488, 561, and
640 nm) and 18 photomultiplier (PMT) detectors (Becton Dickinson), a NovoCyte
Analyzer equipped with three lasers (405, 488, and 640 nm) and 13 PMT detectors
(ACEA Biosciences, Inc), or on a CytoFlex (Beckman Coulter) with four lasers
(405, 488, 561, and 633 nm) and 14 PMT detectors. Antibodies used to determine
phenotype of cells, as well as working concentrations, are listed in Supplementary
table 2. Data were analyzed using FlowJo software (version 10, Tree Star, Ashland,
OR, USA). Individual gating strategies are depicted in relevant ﬁgures and outlined
in ﬁgure legends. FMO controls were utilized to distinguish different populations.
Viability over prolonged culture. To assess the viability over prolonged culture of
HSPC-pDCs or blood pDCs, cells were collected at each time point and subsequently analyzed using ﬂow cytometry. Cells were stained with Zombie aqua as a
viability dye, and viable cell counts were measured and normalized to a ﬁxed
number of counting beads (CytoCount beads; Dako).
Quantitative real-time PCR. Gene expression levels of IFN-α2, IFN-α4, IFN-α16,
IRF7, TLR7, and TLR9 were determined by reverse transcription (RT)-qPCR using
TaqMan detection systems (Life Technologies). Expression levels were normalized
to DAG1, and data are presented as relative expression levels. The following
TaqMan assays were used: IFN-α2; Hs00265051_s1, IFN-α4; Hs01681284_sH,
IFN-α16; Hs03005057_sH, TLR7; Hs01933259_s1, TLR9; Hs00370913_s1, DAG1;
Hs00189308_m1.
Antigen presentation assays. Enriched HSPC-pDCs were primed with IFN-β + γ
for 72 h and subsequently stimulated with R837 (Invivogene, 2.5 µg/mL). After 24 h
stimulation, HSPC-pDCs were pulsed with 1 µg per peptide/mL of CMV (ProMixTM CMV Peptide Pool, ProImmune) or left untreated. After 3 h cells were
washed and subsequently co-cultured with PBMCs from CMV-seropositive
donors. As controls, PBMCs from the same donors were stimulated with 1 µg per
peptide/mL of CMV or left untreated. PBMCs and HSPC-pDCs were co-cultured
at a cell ratio of 10:1 (105 PBMC and 104 HSPC-pDCs) in duplicates in 96-well
plates, 200 µL 10% RPMI supplemented with 20 ng/mL IL-3. After 24 h incubation
supernatants T cell activation was evaluated by measuring IFN-γ levels in
supernatants.
RNA-seq analysis. Library preparation was performed using 1 μg of total RNA
from each sample, using polyA selection. After fragmentation, ﬁrst strand cDNA
synthesis was performed using random hexamers followed by second strand cDNA
synthesis. After double-stranded cDNA puriﬁcation using AMPure XP beads, the
fragments were end-repaired, 3′ adenylated, and NEBNext Adaptor with hairpin
loop structure was ligated. cDNA fragments of preferentially 350 bp in length were
selected using the AMPure XP system and PCR ampliﬁcation was performed to
create the ﬁnal cDNA library. The library was sequenced using Illumina 150 bp
paired-end reads (~30M reads/sample). Library preparation and sequencing was
conducted by Novogene (Sacramento, USA). Transcriptome analysis was performed using Partek Flow built 5.0.16.1128 (St. Louis, USA). Adaptor-trimmed
reads were imported into Partek Flow and aligned to the human reference genome
hg38 using STAR (version 2.5.3a). The aligned reads were annotated to transcriptome (hg38 RefSeq Transcripts 84) using the Partek E/M annotation model
with strict paired-end compatibility required. The aligned reads were normalized
using TPM (transcripts per kilobase million). Genes with extremely low expression
were ﬁltered out based on a minimal expression cutoff of 1.0 TPM across samples;
4732 genes were included in downstream analyses. Differential gene expression was
calculated with using ANOVA in Partek Flow with treatment as a ﬁxed factor and
participant ID as a random factor, as some cell populations were from the same
donor. Lists of differentially expressed genes were generated by using the following
thresholds: absolute fold change >5 and FDR <0.05. Pathway analysis and identiﬁcation of predicted upstream regulators was performed using Ingenuity Pathway
Analysis (IPA) (Qiagen, Redwood City, USA). The calculated z-score predicts the
direction of change (positive z-score indicates increased activation state of
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predicted upstream regulators (orange), and negative value indicates a decrease in
activation state (blue).
Screening of sgRNAs. sgRNAs were initially screened for the capacity to induce
insertions or deletions (Indels) in the immortalized K562 cell line (ATCC). K565
(ATCC) was maintained in RPMI-1640 (Lonza) supplemented with 10% FCS
(HyClone®), 100 µg/mL streptomycin and 200 U/mL penicillin, and 2 mM L-glutamine. Two annealed oligonucleotides carrying the sgRNA target sequences were
cloned into pX330 (pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng
Zhang, Addgene plasmid #42230) as previously described69. The pX330 plasmid
contains a human U6 promotor driving the expression of the sgRNA and a SpCas9
expression cassette (for sgRNA sequences see Supplementary Table 3). Delivery of
sgRNA-px330 plasmid to cells was performed by nucleoporation using the Lonza
4D-NucleofectorTM System (program FF-123). Three days after transfection, Indel
frequencies were quantiﬁed using TIDE (Tracking of Indels by Decomposition)70;
Genomic DNA was extracted and PCR amplicons spanning the sgRNA target site
were generated (for primers see Supplementary Table 4). Puriﬁed PCR products
were then Sanger-sequenced and Indel frequencies quantiﬁed using the TIDE
software (http://tide.nki.nl). A reference sequence (mock-transfected sample) was
used as a control.
Making genetically modiﬁed HSPC-pDCs. sgRNAs directed at MyD88, IFNAR1,
and CCR5 were synthesized by Synthego or TriLink Technologies with the three
terminal nucleotides in both ends chemically modiﬁed with 2′-O-methyl-3′phosphorothioate35. Thawed CD34+ HSPC were initially pre-cultured at low
density (105 cells/mL) for 3 days in CD34+ HSPC medium (SFEM II medium
(STEMCELL Technologies) supplemented with 20 units/mL penicillin, 20 mg/mL
streptomycin, Flt3-L (100 ng/mL), SCF (100 ng/mL), TPO (100 ng/mL), IL-6
(100 ng/mL), SR1 (0.75 µM), and UM171 (35 nM)) before being nucleoporated as
shown previously37–39. Ribonucleoprotein (RNP) complexes were made by incubating Cas9 protein (Integrated DNA Technologies) with sgRNA at a molar ratio
of 1:2.5 at 25 °C for 10 min prior to nucleoporation. Nucleoporation was performed
using the Lonza 4D-NucleofectorTM System (program DZ100). After a 3-day
recovery phase in CD34+ HSPC expansion medium, HSPC medium was changed
to the medium promoting pDC differentiation as previously described.
Statistical analysis. All data were plotted using GraphPad Prism 6.0 (GraphPad
Software, San Diego, CA, USA). Data presented are expressed as means ± standard
error of mean (±SEM). Statistical analysis was performed using one-way ANOVA
or two-way ANOVA, followed by Bonferroni post hoc test, as indicated in the
ﬁgure legends. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Data availability
All relevant datasets generated during and/or analyzed during the current study are
available from the corresponding author upon request.
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